Related Experiment Video

Updated: May 24, 2026

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy
07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

Optimal drug therapy after aspirin-induced upper gastrointestinal bleeding

M Struijk1, D F Postma, S A C van Tuyl

  • 1Department of Internal Medicine, Diakonessenhuis, Utrecht, The Netherlands. m.struijk@students.uu.nl

European Journal of Internal Medicine
|March 6, 2012
PubMed

Insights

Continuing aspirin therapy after upper gastrointestinal bleeding is often beneficial, especially when combined with a proton pump inhibitor, to prevent cardiovascular events. Careful consideration of individual patient factors is crucial when managing recurrent bleeding risks.

Area of Science:

  • Gastroenterology
  • Cardiology
  • Pharmacology

Background:

  • Chronic aspirin use is linked to upper gastrointestinal bleeding (UGIB).
  • Discontinuation of aspirin after UGIB is a common clinical practice.
  • Recent evidence suggests potential benefits of continuing aspirin therapy.

Purpose of the Study:

  • To evaluate the risks and benefits of continuing aspirin therapy after UGIB.
  • To compare aspirin continuation with proton pump inhibitor (PPI) therapy versus discontinuation.
  • To discuss the management of recurrent gastrointestinal bleeding in patients on aspirin.

Main Methods:

  • Review of recent studies and clinical evidence.
  • Analysis of cardiovascular complication rates versus recurrent peptic ulcer bleeding.
  • Consideration of individual patient factors and alternative therapies.

Main Results:

  • Continuation of aspirin with PPIs may reduce cardiovascular complications.
  • Recurrent peptic ulcer bleeding risk is only slightly increased with aspirin and PPI combination.
  • Alternative antiplatelet therapies currently do not offer lower gastrointestinal risks.

Conclusions:

  • Continuing aspirin therapy post-UGIB, particularly with PPIs, is often advisable to mitigate cardiovascular risks.
  • Individualized assessment is necessary to balance bleeding risk against thrombotic event prevention.
  • Future therapies may offer improved gastrointestinal safety profiles.

Related Concept Videos

Peptic Ulcer Disease IV: Management01:26

Peptic Ulcer Disease IV: Management

Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors01:13

Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors

Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists01:28

Acid Suppressive Drugs for Peptic Ulcer Disease: Histamine H2-Receptor Antagonists

Histamine H2 receptors, which are intricately located on the basolateral membrane of parietal cells, play a crucial role in modulating gastric acid secretion. When released from enterochromaffin-like cells, histamine engages H2 receptors, initiating the cyclic AMP (cAMP) pathway. In this pathway, adenylyl cyclase converts ATP into cAMP, elevating intracellular cAMP levels. The activation of protein kinase A follows, stimulating the proton pump. This stimulation prompts the secretion of hydrogen...